Ridgetech Inc (Nasdaq:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, announced on Monday its financial results for the fiscal year ended 31 March 2025.
Revenue totalled USD119.97m, down from USD123.99m in the same period of last year.
Gross profit was USD3.84m, compared to USD4.88m a year earlier, while gross margin was 3.2% compared to 3.9% in the year to 31 March 2024.
Ridgetech reported net income of USD10.20m, or USD1.84 per basic and diluted earnings per share, compared to a net loss of USD4.23m, or USD2.93 per basic and diluted loss per share, for the same period a year ago.
As of 31 March 2025 the company had cash and cash equivalents of USD12.78m, an increase from USD2.30m as of 31 March 2024.
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli